New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 29, 2012
13:51 EDTOREX, ARNA, VVUSVIVUS drug's CV profile viewed positively by FDA, says Rodman & Renshaw
After attending an FDA panel hearing focused on the effects of anti-obesity drugs on cardiovascular systems, Rodman & Renshaw believes that the FDA and the panel are comfortable with the cardiovascular profile of VIVUS' drug, Qnexa. The firm indicates that it doesn't expect the agency to require additional cardiovascular tests before Qnexa is approved, and it reiterates an Outperform rating on VIVUS.
News For VVUS;ARNA;OREX From The Last 14 Days
Check below for free stories on VVUS;ARNA;OREX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 11, 2014
07:06 EDTVVUSVIVUS announces avanafil clinical data presentation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use